On November twenty fifth, Cassava Sciences introduced their experimental Alzheimer’s drug simufilam did not sluggish cognitive or useful decline in its 52-week Part 3 trial….
The submit Cassava Drug Simufilam Fails First Part 3 Trial, Halts Second Part 3 Trial appeared first on Being Affected person.
